Vivos Therapeutics to Participate at the Benzinga Global Small Cap Conference
Vivos Therapeutics (NASDAQ: VVOS) will present at the Benzinga Global Small Cap Conference at 12:15 PM ET on October 27, 2021. The management team, including Chairman and CEO Kirk Huntsman and CFO Brad Amman, will discuss innovative treatments for mild to moderate obstructive sleep apnea (OSA) and snoring in adults. The conference runs from October 27-28, 2021. Interested investors can register for a free pass online. Vivos specializes in non-surgical treatments and has successfully treated over 19,000 patients worldwide.
- None.
- None.
Vivos management to present at 12:15 pm Eastern Time on October 27, 2021
HIGHLANDS RANCH, Colo., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring in adults, today announced that Vivos’ Chairman and Chief Executive Officer, Kirk Huntsman, and Vivos’ Chief Financial Officer, Brad Amman, will be presenting at the online Benzinga Global Small Cap Conference at 12:15 pm ET on Wednesday, October 27, 2021. The Benzinga Global Small Cap Conference will be taking place from October 27-28, 2021.
Investors interested in joining the Vivos presentation can register for a free spectator pass at the link below:
https://www.benzinga.com/events/small-cap/october-2021-global/
A replay of the presentation will be available for view following the presentation on Vivos’ website at: https://vivoslife.com/investor-relations/
About Vivos Therapeutics, Inc.
Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from mild-to-moderate obstructive sleep apnea (OSA). The Vivos treatment involves customized oral appliances and treatment protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for adults with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in over 19,000 patients treated worldwide by more than 1,250 trained dentists.
Combining proprietary technologies and protocols that alter the size, shape and position of the tissues that comprise a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology, for Home Sleep Testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using the Vivos System.
For more information, visit www.vivoslife.com.
About the Benzinga Global Small Cap Conference
The Benzinga Global Small Cap Conference bridges the gap between Small Cap companies, investors, and traders. Learn about small cap investing with clearly defined educational modules, take a look at a curated group of small cap investment opportunities, and connect with the global small cap audience in an intimate, virtual setting.
For more information and/or to register for the conference please visit: https://www.benzinga.com/events/small-cap/october-2021-global/
Cautionary Note Regarding Forward-Looking Statements
This press release, the management presentation discussed herein, and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC's website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos' expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Investor Relations Contact:
Edward Loew
Investor Relations Officer
(602) 903-0095
ed@vivoslife.com
Media Relations Contact:
Joe McIntyre/ Jenny Robles
KCSA Strategic Communications
(856) 381-8996 / (917) 420-1444
jmcintyre@kcsa.com/ jrobles@kcsa.com
FAQ
When will Vivos Therapeutics present at the Benzinga Global Small Cap Conference?
Who will be presenting from Vivos Therapeutics at the conference?
What is the focus of Vivos Therapeutics?
How can investors access the presentation?
What are the key products offered by Vivos Therapeutics?
How many patients has Vivos Therapeutics treated?
